Literature DB >> 2117706

The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.

D Eidelberg1, J R Moeller, V Dhawan, J J Sidtis, J Z Ginos, S C Strother, J Cedarbaum, P Greene, S Fahn, D A Rottenberg.   

Abstract

We studied the metabolic anatomy of typical Parkinson's disease (PD) using [18F]fluorodeoxyglucose (FDG) and [18F]fluorodopa (FDOPA) and positron emission tomography (PET). Fourteen PD patients (mean age 49 years) had FDG/PET scans, of which 11 were scanned with both FDOPA and FDG. After the injection of FDOPA, brain uptake and arterial plasma radioactivity were monitored for 2 h. Striatal FDOPA uptake was analyzed with regard to a two-compartment model, and target-to-background ratios (TBRs) and TBR-versus-time slopes were also calculated. Regional patterns of metabolic covariation were extracted from FDG/PET data using the Scaled Subprofile Model (SSM). SSM pattern weights, FDOPA uptake constants (Ki), TBRs, and TBR slopes were correlated with clinical measures for bradykinesia, rigidity, tremor, gait disturbance, left-right asymmetry, dementia, and overall disease severity. In PD patients, rate constants for FDOPA uptake correlated with individual measures of bradykinesia (p = 0.001) and gait disability (p less than 0.05). SSM analysis revealed a distinct pattern of regional metabolic asymmetries, which correlated with motor asymmetries (p less than 0.001) and left-right differences in Ki (p less than 0.01). Our data suggest that in PD patients, FDG/PET and FDOPA/PET may provide unique and complementary information about underlying disease processes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117706     DOI: 10.1002/mds.870050304

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 2.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

Review 3.  Cognitive differences between patients with left-sided and right-sided Parkinson's disease. A review.

Authors:  Nele Verreyt; Gudrun M S Nys; Patrick Santens; Guy Vingerhoets
Journal:  Neuropsychol Rev       Date:  2011-09-29       Impact factor: 7.444

4.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

Review 5.  The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature.

Authors:  Branislav Veselý; Angelo Antonini; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2015-10-19       Impact factor: 3.575

6.  Assessment of disease progression in parkinsonism.

Authors:  Kotaro Asanuma; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

7.  Morphological differences in Parkinson's disease with and without rest tremor.

Authors:  David H Benninger; Sebastian Thees; Spyros S Kollias; Claudio L Bassetti; Daniel Waldvogel
Journal:  J Neurol       Date:  2009-02-04       Impact factor: 4.849

8.  (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.

Authors:  Valentina Ambrosini; Maria Cristina Marzola; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Cerebral glucose metabolic abnormality in patients with congenital scoliosis.

Authors:  Weon Wook Park; Kuen Tak Suh; Jeung Il Kim; Ja Gyung Ku; Hong Seok Lee; Seong-Jang Kim; In-Ju Kim; Yong-Ki Kim; Jung Sub Lee
Journal:  Eur Spine J       Date:  2008-04-30       Impact factor: 3.134

10.  Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Hiroto Kuwabara; Gregory M Constantine; Chester A Mathis; Robert Y Moore
Journal:  Neurosci Lett       Date:  2007-08-06       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.